In vitro characteristics of highly purified factor VIII concentrates Massimo Morfini Symposium Pages: 123 - 125
Ultrapure plasma factor VIII produced by anti-FVIIIc immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human) M. Griffith Symposium Pages: 131 - 137
Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C Jeanne M. Lusher Symposium Pages: 138 - 141
Antihemophilic factor isolated with monoclonal antibodies Edward D. Gomperts Symposium Pages: 142 - 144
Effects of factor VIII concentrates on the immune system in hemophilic patients Sam Schulman Symposium Pages: 145 - 151
Clinical experience with Hemofil M in a hemophilia patient exhibiting inhibitors J. IngerslevK. Wallevik Symposium Pages: 152 - 154
Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology Randal J. Kaufman Symposium Pages: 155 - 165
In-process controls and characterization of recombinate antihemophilic factor (recombinant) M. GriffithH. KingdonW. Burkart Symposium Pages: 166 - 171
Current status of a recombinant antihemophilic factor VIII clinical trial organized by Baxter I. Scharrer Symposium Pages: 172 - 176
Closing remarks to the Symposium on Advances in Hemophilia Treatment in the 1990s I. Scharrer Report Pages: 177 - 178